Cisplatin + nintedanib + pemetrexed + placebo

Author: jhpg

August undefined, 2024

WebNintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, … WebApr 1, 2024 · Request PDF On Apr 1, 2024, Antoinette J. Wozniak and others published Short report of a phase II trial of nintedanib in recurrent malignant pleural mesothelioma (MPM) Find, read and cite all ...

Review of nintedanib plus pemetrexed/cisplatin in patients with ...

WebApr 4, 2024 · Eligible patients with previously untreated metastatic nonsquamous non–small-cell lung cancer without EGFR/ALK alterations were randomly assigned 2:1 to pembrolizumab 200 mg or placebo once every 3 weeks for up to 35 cycles with pemetrexed and investigator's choice of carboplatin/cisplatin for four cycles, followed … WebJul 24, 2013 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double … dvd dreamworks puss in boots

Nintedanib in combination with pemetrexed and cisplatin for ...

WebOct 1, 2024 · PDF On Oct 1, 2024, Federica Grosso and others published SPS-7Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial Find ... WebPatients received oral nintedanib (150 mg or 200 mg twice daily for 12 weeks) or placebo, in addition to usual neoadjuvant chemotherapy with intravenous gemcitabine 1000 mg/m 2 on days 1 and 8 and intravenous cisplatin 70 mg/m 2 on day 1 of a 3-weekly cycle. The primary endpoint was pathological complete response rate, assessed at cystectomy or ... dvd drive download free for windows 10

Clinical development of nintedanib for advanced non-small-cell …

Nintedanib in combination with pemetrexed and cisplatin …

WebThe intervention group received up to six cycles of pemetrexed and cisplatin plus nintedanib 200 mg twice daily while the control group received chemotherapy plus placebo. Nintedanib and placebo were continued until disease progression. The primary end point was PFS. Eighty-seven patients were randomly assigned 1:1 ratio. WebThe pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of malignant pleural mesothelioma (MPM). The second-line (SL) c… in best chicago spasWebOther strategies to target VEGF have included the use of the angiokinase inhibitor nintedanib in combination with cisplatin and pemetrexed chemotherapy in the Phase III, randomised LUME-Meso trial. 40 This failed to demonstrate a benefit for median PFS for the addition of nintedanib (6.8 versus 7.0 months, HR 1.01 95% CI 0.79–1.30, p = 0.914). dvd drive not not recognized as lightscribe

"WebSep 11, 2024 · Treatment with pemetrexed and cisplatin and either nintedanib or matching placebo was given in 21-day courses. … " - Cisplatin + nintedanib + pemetrexed + placebo

Cisplatin + nintedanib + pemetrexed + placebo

WebReview of nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial J Thorac Dis . 2024 Sep;10(Suppl 26):S3124-S3127. doi: 10.21037/jtd.2024.07.105. WebPemetrexed (Alimta) is administered as 500 mg/m 2 as an intravenous infusion over 10 minutes after pembrolizumab and prior to carboplatin or cisplatin on day 1 of each 21-day cycle for 4 cycles for initial treatment of metastatic non-squamous NSCLC in individuals with a creatinine clearance of 45 mL/min or greater.

Did you know?

WebDec 19, 2016 · ITT analysis of the primary end point showed that treatment with nintedanib plus pemetrexed resulted in a significant prolongation of PFS compared with placebo plus pemetrexed (4.4 vs. 3.6 months with a HR of 0.83 and a p value of 0.04). WebNov 1, 2024 · This concept was based on the following reasoning: pemetrexed plus cisplatin is a standard first-line regimen in MPM; a phase III trial in advanced MPM confirmed that treatment with pemetrexed as a second-line regimen resulted in improved progression-free survival (PFS) over best supportive care. 5 In a Dutch single-arm …

WebSep 18, 2024 · This study aims to evaluate the safety of nintedanib when used in combination with pemetrexed and cisplatin in patients with unresectable MPM. This randomized, double-blind, placebo-controlled, phase 3 trial included a total of 458 patients with unresectable epithelioid MPM. WebMar 27, 2024 · For unresectable MPM, a regimen of pemetrexed (Pem) and cisplatin (Cis) was approved as the standard of care in first-line treatment by the FDA in 2004 . Currently, numerous studies are being conducted to explore the efficacy of novel agents and regimens for MPM first-line treatment. ... Regardless, any kind of therapy other than placebo may …

WebThis is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by … WebThis is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin followed by placebo for the treatment of patients with unresectable malignant pleural mesothelioma.

WebMay 16, 2013 · This randomized, double-blinded study evaluated nintedanib – a triple angiokinase inhibitor – plus pemetrexed compared to pemetrexed plus placebo in patients with advanced non-squamous NSCLC not responding to, or who progressed after, first-line chemotherapy. 20 LUME-Lung 2 did not pass the pre-defined interim futility analysis from ...

WebApr 9, 2024 · Introduction: Mesothelioma is a rare and aggressive cancer that affects the lining of the lungs, abdomen, or heart. It is most commonly caused by exposure to asbestos fibers, and unfortunately, it has a poor prognosis. The standard treatment options for mesothelioma include surgery, chemotherapy, and radiation therapy, but these … in best in kishidaWebApr 11, 2024 · Nintedanib doses were permitted to be reduced to 150 mg, 100 mg, or 50 mg (or to 100 mg or 50 mg for patients with GFR 40–60 mL/min). Both gemcitabine and … dvd drive not playingWebDec 1, 2024 · Placebo, pemetrexed 500 mg/m 2, and investigator's choice of cisplatin 75 mg/m 2 or carboplatin AUC 5 mg/mL/min intravenously on Day 1 of each 21-day cycle for 4 cycles followed by placebo and pemetrexed 500 mg/m 2 intravenously every 3 weeks. dvd drive for chromebookWebMay 15, 2024 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural … in best nyc spasWeband safety of nintedanib versus placebo, each in combination with up to 6 cycles of pemetrexed/cisplatin, followed by nintedanib or placebo maintenance, in patients with previously untreated, unresectable malignant pleural mesothelioma (MPM)4 In Phase II, nintedanib demonstrated an improvement in the primary dvd drive not being recognized windows 10WebJ Clin Oncol 31(23):2895–2902 CrossRef Paz-Ares LG et al (2013) PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. in best shapeWebThe intervention group received up to six cycles of pemetrexed and cisplatin plus nintedanib 200 mg twice daily while the control group received chemotherapy plus … dvd drive not recognized as video